Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Abstract

We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.